Australien - engelsk - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin, quantity: 100 iu/ml - injection, suspension - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide; protamine sulfate; metacresol; zinc oxide; glycerol; dibasic sodium phosphate heptahydrate; phenol - for the treatment of insulin dependent diabetic patients.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin, quantity: 100 iu/ml - injection, suspension - excipient ingredients: zinc oxide; water for injections; phenol; sodium hydroxide; glycerol; metacresol; protamine sulfate; hydrochloric acid; dibasic sodium phosphate heptahydrate - for the treatment of insulin dependent diabetic patients.

USA - engelsk - NLM (National Library of Medicine)

aramis inc. - avobenzone (unii: g63qqf2nox) (avobenzone - unii:g63qqf2nox), homosalate (unii: v06sv4m95s) (homosalate - unii:v06sv4m95s), octisalate (unii: 4x49y0596w) (octisalate - unii:4x49y0596w), oxybenzone (unii: 95oos7ve0y) (oxybenzone - unii:95oos7ve0y) - - helps prevent sunburn - if used as directed with other sun protection measures (see directions ), decreases the risk of skin cancer and early skin aging caused by the sun

Australien - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

troy laboratories pty ltd - tulathromycin - parenteral liquid/solution/suspension - tulathromycin antibiotic active 100.0 mg/ml - antibiotic & related

Israel - engelsk - Ministry of Health

incyte biosciences israel ltd, israel - ponatinib as hydrochloride - coated tablets - ponatinib as hydrochloride 15 mg - ponatinib - iclusig is indicated in adult patients with: • chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation • philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation.

Israel - engelsk - Ministry of Health

incyte biosciences israel ltd, israel - ponatinib as hydrochloride - coated tablets - ponatinib as hydrochloride 15 mg - ponatinib - iclusig is indicated in adult patients with: • chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation • philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation.

Israel - engelsk - Ministry of Health

incyte biosciences israel ltd, israel - ponatinib as hydrochloride - coated tablets - ponatinib as hydrochloride 45 mg - ponatinib - iclusig is indicated in adult patients with: • chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation • philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation.

Israel - engelsk - Ministry of Health

incyte biosciences israel ltd, israel - ponatinib as hydrochloride - coated tablets - ponatinib as hydrochloride 45 mg - ponatinib - iclusig is indicated in adult patients with: • chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation • philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation.

Singapore - engelsk - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - cardiovascular - the intended use of the carto® 3 system is catheter-based cardiac electrophysiological (ep) procedures. the carto® 3 system provides information about the electrical activity of the heart and about catheter location during the procedure. the system can be used on patients who are eligible for a conventional electrophysiological procedure.

Singapore - engelsk - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - cardiovascular - the celsius fltr catheter is indicated for cardiac electrophysiological mapping (stimulation and recording) and, when used in conjunction with a radiofrequency generator, for cardiac ablation.